Journey Medical Corp splits its revenue into 11 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was Qbrexza at $25.0 million, 41% of the total.
USD in millions. The percent under a figure is the change from the year before.
| Line |
FY 2026
Jun 30, 2026
|
FY 2025
Dec 31, 2025
|
FY 2024
Dec 31, 2024
|
FY 2023
Dec 31, 2023
|
FY 2022
Dec 31, 2022
|
FY 2021
Dec 31, 2021
|
|---|---|---|---|---|---|---|
| Revenue |
67
|
61
|
55
|
60
|
71
|
63
|
| Qbrexza |
23
-9.2%
share 34.5%
|
25
share 40.8%
|
—
|
25
share 42.6%
|
—
|
—
|
| Qbrexa |
—
|
—
|
—
|
—
|
—
|
17
share 27.0%
|
| Emrosi |
24
share 36.2%
|
15
share 24.1%
|
—
|
—
|
—
|
—
|
| Accutane |
13
-16.2%
share 18.7%
|
13
-33.6%
share 21.0%
|
19
-3.8%
share 35.2%
|
20
share 33.8%
|
—
|
10
share 15.9%
|
| Ximino |
—
|
—
|
—
|
—
|
—
|
8
share 13.1%
|
| Foam Franchise Products Amzeeq Zilxi |
5
share 7.8%
|
6
share 9.6%
|
—
|
—
|
—
|
—
|
| Exelderm |
—
|
—
|
—
|
—
|
—
|
5
share 8.5%
|
| Amzeeq |
—
|
—
|
5
-19.2%
share 9.1%
|
6
share 10.4%
|
—
|
—
|
| Other Legacy |
2
-49.4%
share 2.7%
|
3
-30.9%
share 4.5%
|
4
-33.1%
share 7.2%
|
6
share 9.9%
|
—
|
—
|
| Zilxi |
—
|
—
|
2
-16.3%
share 3.0%
|
2
share 3.3%
|
—
|
—
|
| Other Branded Products |
—
|
—
|
—
|
—
|
—
|
0
share 0.1%
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- DERM (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Scottsdale, AZ
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1867066
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.